Aperio Group’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Aperio Group’s Portfolio SCLN Stock Details SCLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-43,403	Closed	-$486K	–	2285
2017 Q3	$486K	Buy	43,403 +14,593	+51%	+$161K	﹤0.01%	1673
2017 Q2	$317K	Buy	28,810 +5,026	+21%	+$50.3K	﹤0.01%	1866
2017 Q1	$233K	Buy	23,784 +11,608	+95%	+$116K	﹤0.01%	1963
2016 Q4	$132K	Sell	12,176 -1,007	-8%	-$10.1K	﹤0.01%	2062
2016 Q3	$135K	Buy	13,183 +1,690	+15%	+$18.4K	﹤0.01%	1998
2016 Q2	$150K	Buy	11,493 +1,125	+11%	+$14.7K	﹤0.01%	1930
2016 Q1	$114K	Buy	+10,368	New	+$92.2K	﹤0.01%	1962

Aperio Group's SCLN Position: Q4 2017 in Review

Aperio Group sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 43,403 shares — an estimated $486K sold.

Aperio Group first reported a position in SCLN in Q1 2016 and held it in 7 quarters. The position peaked at $486K in Q3 2017. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.

Aperio Group reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
Aperio Group sold 43,403 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $486K.
Aperio Group first reported a position in Sciclone Pharmaceuticals Inc in Q1 2016 and held it in 7 quarters.
Aperio Group's Sciclone Pharmaceuticals Inc position peaked at $486K in Q3 2017.
0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.

Based on Aperio Group's 13F filing for Q4 2017, filed 2 Feb 2018.